Avastin optimum dosing schedule defined

Article

When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

When using bevacizumab (Avastin) to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

Dr Luis Arias of the Department of Ophthalmology at the Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain and colleagues segregated patients into two groups: the LD group received bevacizumab monthly for three months followed by as-needed dosing, and the PRN group received a single injection of bevacizumab followed by as-needed dosing. Doctors considered that another injection of bevacizumab was necessary if any of the following factors were present: macular oedema (either persistent or recurrent), pigment epithelial detachment or subretinal fluid.

At six months, no ocular or systemic side effects were observed in either group. In the LD group, mean visual acuity increased by 13.7 letters, and 36% of subjects had gained 15 or more letters; mean foveal thickness decreased by 91.3 µm. In comparison, in the PRN group, mean visual acuity increased by only 4.6 letters, and just 12% of subjects had gained 15 or more letters; mean foveal thickness decreased by 48.2 µm.

Thus the researchers concluded that an LD regime was a more effective and equally safe treatment protocol when compared with PRN dosing.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.